Sign in →

Test Code F2ISO F2-Isoprostanes, Random, Urine

Reporting Name

F2-Isoprostanes, U

Useful For

Assessment of in vivo lipid peroxidation

 

Considered to be an index of systemic oxidative stress over time

Additional Tests

Test ID Reporting Name Available Separately Always Performed
CRETR Creatinine, Random, U No Yes

Testing Algorithm

When F2-isoprostanes testing is performed, urine creatinine will always be performed at an additional charge.

Method Name

F2ISO: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

CRETR: Enzymatic Colorimetric Assay

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Urine


Specimen Required


Patient Preparation: Patient should not take nonsteroidal anti-inflammatory drugs within the 72 hours or aspirin within the 2 weeks prior to specimen collection.

Supplies: Sarstedt 5 mL Aliquot Tube (T914)

Container/Tube: Plastic urine tube

Specimen Volume: 5 mL

Collection Instructions:

1. Collect a random urine specimen.

2. No preservative.


Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Urine Refrigerated (preferred) 7 days
  Frozen  30 days
  Ambient  7 days

Reject Due To

  All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Reference Values

≥18 years: ≤1.0 ng/mg creatinine

Reference values have not been established for patients who are younger than 18 years of age

Day(s) Performed

Tuesday

CPT Code Information

82542

LOINC Code Information

Test ID Test Order Name Order LOINC Value
F2ISO F2-Isoprostanes, U 90783-2

 

Result ID Test Result Name Result LOINC Value
88677 15-F2t-Isoprostane, U 90783-2

Clinical Information

Oxidative stress results from an imbalance of reactive oxygen species resulting in peroxidation of biomolecules. 15-F2t-isoprostane (F2ISO, also referred to as 8-iso-PGF2alpha or 8-isoprostane) is an F2-isoprostane and its measurement is considered the "gold standard” test for quantifying lipid peroxidation in vivo. F2ISO is a potent vasoconstrictor, induces vascular smooth muscle cell proliferation, and increased aspirin resistance to platelet aggregation. Elevated urinary F2ISO concentrations are associated with the presence and extent of coronary artery stenosis, peripheral artery disease, and increased risk of post-operative atrial fibrillation.

 

Urinary F2ISO concentrations are lowered by aerobic exercise training, smoking cessation, and fenofibrate therapy.

Interpretation

Elevated urinary F2-isoprostanes reflect widespread oxidative stress and systemic burden of lipid peroxidation end products. Quantitation of F2-isoprostanes in urine is highly dependent upon the methodology utilized; however, mass spectrometry methods (gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry) assays yield superior sensitivity and analytical specificity compared with immunoassays.

 

F2-isoprostanes demonstrate superior clinical sensitivity compared to other oxidative stress biomarkers but lack clinical specificity for any particular disease. Pharmacological treatment with antioxidant supplementation, hypoglycemic agents in diabetes, smoking cessation, and weight reduction have all been shown to decrease production of F2-isoprostanes.

Cautions

For the most accurate assessment of lipid oxidation status, individuals should not be on aspirin or other nonsteroidal anti-inflammatory drugs, have smoked, or have had acute changes in statin mono- or combination therapies.

 

Patients should not take nonsteroidal anti-inflammatory drugs within 72 hours or aspirin within 2 weeks prior to providing a urine specimen for analysis.

Method Description

15-F2t-Isoprostane is separated and quantified in urine by liquid chromatography-tandem mass spectrometry (LC-MS/MS).(Unpublished Mayo method)

Report Available

2 to 9 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.